Cilta-Cel Allows for Treatment-Free Period in Early R/R Multiple Myeloma

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the significance of the FDA approval of cilta-cel in relapsed/refractory multiple myeloma.

Related Keywords

New York ,United States ,Saadz Usmani , ,Johnson ,Oncologic Drugs Advisory Committee ,Janssen Biotech Inc ,Meeting Of The Oncologic Drugs Advisory Committee ,Drugs Advisory Committee ,Myeloma Service ,Memorial Sloan Kettering Cancer Center ,